◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Sino Biopharmaceutical Limited (1177) Financial History

Name: Sino Biopharmaceutical Limited (1177) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-08-10

Sino Biopharmaceutical Limited (1177) operates in the Biotechnology industry and is headquartered in Wan Chai, Hong Kong with about 21,435 employees. Its market capitalization is roughly CNY 90 billion. In the fiscal year ended 2025-12-31, 1177 reported CNY 31.8B in revenue and CNY 2.3B in net income.

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others.

Interactive charts & full statements →

1177 Revenue & Earnings History — Annual Income Statement

Income statement	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Revenue	CNY 31.8B	CNY 28.9B	CNY 26.2B	CNY 26.0B	—
Gross Profit	CNY 26.1B	CNY 23.5B	CNY 21.2B	CNY 21.5B	—
Operating Income (EBIT)	CNY 6.9B	CNY 6.3B	CNY 6.1B	CNY 5.5B	—
Net Income	CNY 2.3B	CNY 3.5B	CNY 2.3B	CNY 2.5B	—

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

1177 Free Cash Flow History

Cash flow	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Dividends Paid	(CNY 1.5B)	(CNY 1.8B)	(CNY 633M)	(CNY 1.3B)

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

1177 Balance Sheet History

Balance sheet	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Assets	CNY 76.0B	CNY 65.4B	CNY 63.6B	CNY 64.1B	—
Total Liabilities	CNY 33.9B	CNY 22.6B	CNY 25.4B	CNY 26.1B	—

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 1177 viewer.

Other Companies in Biotechnology

6990 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. — $129 billion
VRTX · Vertex Pharmaceuticals — $128 billion
4587 · PeptiDream Inc. — $127 billion
9926 · Akeso, Inc. — $92 billion
4565 · Nxera Pharma Co., Ltd. — $85 billion
REGN · Regeneron Pharmaceuticals — $83 billion
1548 · Genscript Biotech Corporation — $54 billion
9995 · RemeGen Co., Ltd. — $51 billion

← 1176 All “0-9” companies 1179 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.